Genaissance Pharmaceuticals and INTEC Web and Genome Informatics Corporation Announce Commercialization Progress in Japan
NEW HAVEN, Conn., and TOKYO, Dec. 4 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) and INTEC Web and Genome Informatics Corporation (Tokyo: W&G) (INTEC W&G) announced today an agreement with Tokyo Women's Medical University pursuant to which Genaissance will provide HAP(TM) Typing services for use in a drug response study conducted in Japan.
"We have developed a strong relationship with Genaissance and are very pleased to complete our first agreement on their behalf in Japan," said Munehiro Sueoka, President of INTEC W&G. "Genaissance's HAP(TM) Technology is well respected in the Japanese market and we believe numerous Japanese government agencies and pharmaceutical companies plan to conduct genetic variation research over the next few years. We plan to capitalize on those opportunities."
"As pharmacogenomics becomes a cornerstone of pharmaceutical development and marketing, we are excited about our prospects in the Japanese market," said Kevin Rakin, President and Chief Executive Officer for Genaissance. "By combining INTEC's reputation and marketing efforts with our industry leadership, customers in Japan have access to a local company with world-class pharmacogenomic products and services."
INTEC W&G offers leading-edge technologies and advanced information systems to a wide range of customers, including corporations, universities and research institutes in the fields of bioscience and information technology. INTEC W&G is a subsidiary of INTEC Inc., a company with 14 subsidiaries, over 5,000 employees and annual revenues for the year ended March 2003 of 91.94 billion Yen (approximately $843 million).
Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of a new generation of DNA-based diagnostic and therapeutic products. Genaissance markets its technology, clinical development skills and pharmacogenomic services to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with major pharmaceutical, diagnostic and biotechnology companies. Genaissance is headquartered in Science Park in New Haven, Connecticut. Visit the company's website at www.genaissance.com. |
